Under the category of the OTC/Nutraceutical products are listed the products which are sold without prescription. Members of Farmavita.net are invited to publish their out-license offers in this Category.




There is on-going development of  generic EU CTD Dossier of  Irbesartan, tablets, 75-150-300 mg.

Dossier should be available in October 2006.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.


Irbesartan is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Nephropathy in Type 2 Diabetic Patients

Irbesartan is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. In this population, Irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation)

More details at http://www.rxlist.com/cgi/generic/irbesart.htm 

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 34

Advertiser details

Contact Advertiser

Add comment


Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

Lokking for EU CTD Dossiers for traditional...
Member of  Farmavita.Net from EU is looking to...
We are looking to acquire Azathioprine tablet...
I am looking for a good quality dossier with...
We offer for outlicensing European e-CTD...
Novel herbal based throat pastilles with...
We are looking for EU-CTD dossier...